<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558932</url>
  </required_header>
  <id_info>
    <org_study_id>IP3mesov1</org_study_id>
    <nct_id>NCT03558932</nct_id>
  </id_info>
  <brief_title>IP3R Modulation by Cancer Genes in Mesothelioma</brief_title>
  <official_title>IP3R Modulation by Cancer Genes Bcl-2 &amp; PKM2 in Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms
      and signal transduction
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pleural biopsy</measure>
    <time_frame>5 years</time_frame>
    <description>Biopsy</description>
  </primary_outcome>
  <other_outcome>
    <measure>Immunoblotting</measure>
    <time_frame>5 years</time_frame>
    <description>biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytometric analysis (FACS-based approaches)</measure>
    <time_frame>5 years</time_frame>
    <description>biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Live cell imaging for Ca2+-signaling</measure>
    <time_frame>5 years</time_frame>
    <description>biopsy</description>
  </other_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pleural biopsy</intervention_name>
    <description>diagnostic sampling</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      pleural biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        mesothelioma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicion of mesothelioma

          -  referral for diagnostic thoracoscopy

        Exclusion Criteria:

          -  contra-indication for thoracoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Yserbyt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic university Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonas Yserbyt</last_name>
    <phone>+32 16 34 68 01</phone>
    <email>jonas.yserbyt@uzleuven.be</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Yserbyt Jonas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

